Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic control, but more recent studies have now shown that their benefits extend to cardiovascular and kidney outcomes. The recent addition of data on the novel mineralocorticoid receptor antagonist (MRA) gives us another approach to further decrease the residual risk of diabetic kidney disease progression. In this review we describe the mechanism of action, key studies, and possible adverse effects related to these three classes of medications. The management of type 2 diabetes now includes an increasing number of medications for the management of comorbidities in a patient population at significant risk of cardiovascular disease and progression of chronic kidney disease. It is from this perspective that we seek to outline the rationale for the sequential and/or combined use of SGLT2 inhibitors, GLP-1 RA and MRAs in patients with type 2 diabetes for heart and kidney protection.
Citations
Citations to this article as recorded by
Relative and Absolute Risks of Adverse Events with Real-World Use of SGLT2 Inhibitors in CKD Ayodele Odutayo, Adeera Levin Clinical Journal of the American Society of Nephrology.2023; 18(5): 557. CrossRef
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim Endocrinology and Metabolism.2023; 38(1): 43. CrossRef
Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis Eun Sil Koh, Gheun-Ho Kim, Sungjin Chung Endocrinology and Metabolism.2023; 38(4): 359. CrossRef
SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model A Young Sim, Da Hyun Choi, Jong Youl Kim, Eun Ran Kim, A-ra Goh, Yong-ho Lee, Jong Eun Lee Biomedicine & Pharmacotherapy.2023; 168: 115755. CrossRef
Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease Emma S. Speedtsberg, Martin Tepel Frontiers in Endocrinology.2023;[Epub] CrossRef
Management of CKD Nimrit Goraya, Jennifer D. Moran Nephrology Self-Assessment Program.2022; 21(2): 146. CrossRef
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy Peter Kolkhof, Amer Joseph, Ulrich Kintscher Pharmacological Research.2021; 172: 105859. CrossRef
Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression Ayodele Odutayo, Bruno R. da Costa, Tiago V. Pereira, Vinay Garg, Samir Iskander, Fatimah Roble, Rahim Lalji, Cesar A. Hincapié, Aquila Akingbade, Myanca Rodrigues, Arnav Agarwal, Bishoy Lawendy, Pakeezah Saadat, Jacob A. Udell, Francesco Cosentino, Peter Journal of the American Heart Association.2021;[Epub] CrossRef
Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus Luis D’Marco, María Jesús Puchades, Lorena Gandía, Claudia Forquet, Elena Giménez-Civera, Nayara Panizo, Javier Reque, Isabel Juan-García, Valmore Bermúdez, José Luis Gorriz touchREVIEWS in Endocrinology.2021; 17(2): 84. CrossRef
Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review Jorge I. Fonseca-Correa, Ricardo Correa-Rotter Frontiers in Medicine.2021;[Epub] CrossRef